Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: A "split-sample" study

Cancer Cytopathology

Volumn 117, Issue 3, 2009, Pages 167-173

  Sullivan, Peggy S ^a   Nooraie, Farzad ^a   Sanchez, Hope ^b   Hirschowitz, Sharon ^a   Levin, Mary ^a   Nagesh Rao, P ^a   Rao, Jianyu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANTA BARBARA COTTAGE HOSPITAL   (United States)

Author keywords

Bladder neoplasms; Cystoscopy; Cytology; Fluorescence in situ hybridization; Monoclonal antibodies

Indexed keywords

ARTICLE; BLADDER TUMOR; COMPARATIVE STUDY; CYSTOSCOPY; CYTODIAGNOSIS; HUMAN; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; URINE; UROTHELIUM;

CYSTOSCOPY; CYTODIAGNOSIS; HUMANS; NEOPLASM RECURRENCE, LOCAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 70149119519     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20026     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008; 58: 71-96.
2. Placer J, Espinet B, Salido M, Sole F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology. Eur Urol. 2002; 42: 547-552.
3. Junker K, Fritsch T, Hartmann A, Schulze W, Schubert J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res. 2006; 114: 279-283.
4. Lodde M, Mian C, Comploj E, et al. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology. 2006; 67: 950-954.
5. Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol. 2004; 22: 16-19.
6. Toma MI, Friedrich MG, Hautmann SH, et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol. 2004; 22: 145-149.
7. Mian C, Lodde M, Comploj E, et al. Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma. Cytopathology. 2003; 14: 338-342.
8. Tetu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol. 2005; 18: 83-89.
9. Lodde M, Mian C, Negri G, et al. Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology. 2003; 61: 243-247.
10. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol. 1999; 161: 1486-1489.
11. Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000; 2: 116-123.
12. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002; 168: 1950-1954.
13. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol51: 1275-1280, 2007; discussion 1280.
14. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003; 169: 2101-2105.
15. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998; 22: 1435-1448.
16. Messing EM, Teot L, Korman H, et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol. 2005; 174: 1238-1241.
17. Pfister C, Chautard D, Devonec M, et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol. 2003; 169: 921-924.
18. Mian C, Maier K, Comploj E, et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer. 2006; 108: 60-65.
19. Piaton E, Daniel L, Verriele V, et al. Improved detection of urothelial carcinomas with fluorescence immunocyto-chemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study. Lab Invest. 2003; 83: 845-852.
20. Gudjonsson S, Isfoss BL, Hansson K, et al. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2008; 54: 402-408.
21. Olsson H, Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol. 2001; 35: 280-282.
22. Laudadio J, Keane TE, Reeves HM, et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005; 96: 1280-1285.